Literature DB >> 16335855

Optimising acid inhibition treatment.

Fernando Gomollón1, Xavier Calvet.   

Abstract

Acid inhibition is safe and useful in several clinical settings. Proton pump inhibitors are more effective than H2-receptor antagonists in virtually all cases. Proton pump inhibitors should be used in: the eradication of Helicobacter pylori; the treatment of non-H. pylori-related peptic ulcer healing; for the prevention and treatment of non-steroidal anti-inflammatory drug-induced upper digestive lesions; for bleeding peptic lesions; and, especially, in the short-term and long-term control of gastro-oesophageal reflux disease. The timing, the dosing and the specific drugs should be adapted to the particular patient, clinical situation and local factors. For instance, in a patient with active bleeding from a duodenal ulcer, intravenous constant infusion should be the preferred treatment. When seeking oral 'potent' acid inhibition (refractory gastro-oesophageal reflux disease, and perhaps Barrett's oesophagus), available data suggest that the pharmacological and clinical profiles of esomeprazole are slightly better.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16335855     DOI: 10.2165/00003495-200565001-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  47 in total

Review 1.  [Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference].

Authors:  J P Gisbert; X Calvet; F Gomollón; R Sáinz
Journal:  Med Clin (Barc)       Date:  2000-02-12       Impact factor: 1.725

2.  Proton pump inhibitors: better acid suppression when taken before a meal than without a meal.

Authors:  J G Hatlebakk; P O Katz; L Camacho-Lobato; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

3.  Are we underestimating acid reflux?

Authors:  S J Spechler
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

Review 4.  Single-enantiomer drugs: elegant science, disappointing effects.

Authors:  Peter Mansfield; David Henry; Anne Tonkin
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  [Differences in the release of omeprazole in 4 commercial preparations: influence of pH and ionic concentration].

Authors:  M A Navarro; N Raei; F Torres; L Granero; E García-Zaragoza; J V Esplugues; J Esteban Peris
Journal:  Gastroenterol Hepatol       Date:  1998-02       Impact factor: 2.102

6.  Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration.

Authors:  S G Chiverton; C W Howden; D W Burget; R H Hunt
Journal:  Aliment Pharmacol Ther       Date:  1992-02       Impact factor: 8.171

7.  Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.

Authors:  M Vergara; M Vallve; J P Gisbert; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2003-09-15       Impact factor: 8.171

8.  A comparison of omeprazole and placebo for bleeding peptic ulcer.

Authors:  M S Khuroo; G N Yattoo; G Javid; B A Khan; A A Shah; G M Gulzar; J S Sodi
Journal:  N Engl J Med       Date:  1997-04-10       Impact factor: 91.245

9.  Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.

Authors:  Tina M Ours; W Keith Fackler; Joel E Richter; Michael F Vaezi
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

10.  Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding.

Authors:  Alan Barkun; Marc Bardou; John K Marshall
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  1 in total

1.  Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.

Authors:  Tsutomu Nishida; Masahiko Tsujii; Hirohisa Tanimura; Shusaku Tsutsui; Shingo Tsuji; Akira Takeda; Atsuo Inoue; Hiroyuki Fukui; Toshiyuki Yoshio; Osamu Kishida; Hiroyuki Ogawa; Masahide Oshita; Ichizo Kobayashi; Shinichiro Zushi; Makoto Ichiba; Naoto Uenoyama; Yuichi Yasunaga; Ryu Ishihara; Mamoru Yura; Masato Komori; Satoshi Egawa; Hideki Iijima; Tetsuo Takehara
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.